Metabolic reprogramming in adenomyosis: current evidence, biological mechanisms and therapeutic perspectives
Frontiers in Endocrinology · 20.11.2026 · 17
DOI: 10.3389/fendo.2026.2019610 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Endocrinology, online erschienen am 20.11.2026. Verfasst von Mengjie Shi und 8 weiteren Autor:innen. Die Arbeit nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Adenomyosis (AM) is a common reproductive disorder in which endometrial glands and stroma are present within the myometrium. Although endocrine, inflammatory, fibrotic and tissue-injury mechanisms are well described, the metabolic adaptations associated with lesion persistence, tissue repair and the uterine microenvironment are only beginning to be defined. At present, no metabolic biomarker has been validated for routine selection of AM treatment. Main body Recent human metabolomic, lipidomic, transcriptomic and functional studies indicate alterations in glycolysis, mitochondrial metabolism, lipid metabolism, redox regulation and ferroptosis-related pathways. Importantly, these changes are context dependent. Reduced glycolytic activity has been associated with impaired eutopic endometrial repair and heavy menstrual bleeding, whereas enhanced glycolysis has been reported in lesion-containing myometrium; increased cytochrome-c oxidase and ATP synthase content has also been reported in endometrial tissue from women with AM. Myometrial lipidomics and immune–metabolic analyses further support heterogeneous metabolic states. We evaluate how these alterations may interact with hypoxia, inflammation, fibrosis, angiogenesis and endocrine signalling while distinguishing direct AM evidence from inference derived from other disease models. We also examine whether traditional Chinese medicine (TCM) blood-stasis-related phenotypes can serve as clinically defined strata for prospective metabolic studies. Current evidence does not justify assigning any TCM syndrome to a specific metabolic pathway or treating these phenotypes as validated molecular subtypes. Finally, we discuss established hormonal treatment alongside emerging metabolism-related strategies, including metformin, glycolysis modulation, ferroptosis-related approaches, sphingosine-1-phosphate (S1P) signalling and TCM-derived interventions.
Conclusions
Metabolic reprogramming is an emerging component of AM biology, but the available evidence supports tissue- and phenotype-specific alterations rather than a single global metabolic state. A disease-wide statement such as “AM exhibits enhanced glycolysis” is insufficiently precise. Prospectively, compartment-resolved and flux-based studies are required before metabolic signatures can be translated into validated biomarkers or treatment-selection tools.
Zitieren
APA
Shi, M., Cao, M., Zhong, C., Li, Y., Wang, Q., Xie, Q., Mao, H., Shen, X., & Deng, J. (2026). Metabolic reprogramming in adenomyosis: current evidence, biological mechanisms and therapeutic perspectives. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2019610
Vancouver
Shi M, Cao M, Zhong C, Li Y, Wang Q, Xie Q, et al. Metabolic reprogramming in adenomyosis: current evidence, biological mechanisms and therapeutic perspectives. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2019610
BibTeX
@article{Shi2026,
author = {Shi, Mengjie and Cao, Mengdong and Zhong, Chao and Li, Yanhao and Wang, Qiaoyu and Xie, Qi and Mao, Haiqin and Shen, Xue and Deng, Jie},
title = {Metabolic reprogramming in adenomyosis: current evidence, biological mechanisms and therapeutic perspectives},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2019610}
}
EUVIMED